A peptide peak in a blank after a concentrated sample can be carryover from the analytical system. Before rejecting a supplier lot or reporting a low-level impurity, inspect the injection sequence and compare different blank types. The investigation needs to distinguish residue from an earlier injection, contamination introduced during preparation and genuine material in the sample being measured.
Start with the sequence that produced the unexpected peak
Retain the injection order, sample identities and the method version. A chromatogram detached from that sequence can hide the most useful clue: what entered the instrument immediately before the suspect result. Compare the peak’s retention time and mass-spectrometric evidence with the preceding material.
Carryover is one possible explanation when a target-related signal appears after a high sample and declines in later blanks. Persistent signals can also come from preparation materials, solvents or another system source. The pattern directs the next check; it does not, by itself, prove the location of the problem.
Waters’ carryover guidance describes residue from a previous injection appearing in later samples and identifies wash effectiveness and method conditions as relevant factors. Apply those principles to the peptide and instrument configuration under investigation.
Use blanks that separate the competing explanations
“Blank” needs a definition in the report. A vial of fresh solvent, a preparation blank and a matrix blank have different histories. Comparing them can identify whether an interfering substance entered during preparation or was already present in the materials used.
| Check | Question it can help answer |
|---|---|
| Fresh solvent blank | Is the signal present without the sample-preparation process? |
| Preparation blank | Could tubes, tips, reagents or handling contribute the signal? |
| Relevant matrix blank | Does the formulation background produce an interfering response? |
| Blank after a high sample | Does injection history affect the next result? |
Use independent blank vials when the investigation requires them. Repeated access to one vial can add another contact history to the experiment. Keep preparation records and sample positions with the chromatographic files so another reviewer can reconstruct the comparison.
State the denominator when reporting carryover
Two percentages can describe the same blank signal and lead to very different impressions. A response expressed relative to the previous high sample answers a different question from the response expressed relative to a low calibrator. Record the denominator in the method and report.
A worked signal example
Suppose a high sample produces 1,000,000 response units and the following blank produces 600. The blank is 0.06% of the high response. If a low calibrator produces 3,000 units, that same blank equals 20% of the low-calibrator response. These are hypothetical values used to show the arithmetic, not instrument performance data or a proposed acceptance limit.
The result can therefore look small on a full-scale chromatogram while being important to a low-level measurement. Review the interference relative to the analytical decision the method must support, including any affected impurity-reporting level.
Do not borrow an acceptance limit without its scope
ICH M10, adopted on 24 May 2022, addresses bioanalytical method validation and study sample analysis. For chromatographic methods, it describes assessment after the highest calibration standard and limits relative to the lower limit of quantification: 20% for the analyte response and 5% for the internal-standard response.
Those figures belong to M10’s bioanalytical context. They are not a universal release criterion for an HPLC purity method on a research peptide powder. A raw-material method needs an acceptance criterion justified by its intended measurement and the consequences of an interfering signal.
Likewise, an instrument manufacturer’s advertised carryover specification belongs to its stated test conditions. It cannot establish performance for every peptide, matrix and method transferred onto that instrument.
Confirm the improvement under the conditions that failed
Investigate wash effectiveness, sample compatibility with the wash system, relevant contact surfaces and insufficient removal of retained material. Follow the instrument manufacturer’s instructions when evaluating hardware. A stronger wash can introduce another problem if it causes sample or matrix precipitation.
Waters’ ghost-peak troubleshooting note describes diagnostic comparisons that help separate mobile-phase, column and injector-related sources. These comparisons provide evidence for a root cause; changing several factors together makes that evidence harder to interpret.
After a proposed correction, repeat the challenge relevant to the method, then assess affected sample results under the laboratory’s procedure. Preserve the original data. A clean run obtained after unexplained changes does not document which prior results remain usable.
What a buyer should request from the testing laboratory
Request the sequence, blank definitions, response calculations and acceptance rationale alongside the chromatograms. If a laboratory reports a peptide impurity that may be injection-history dependent, ask how it excluded carryover before assigning the signal to the supplied lot.
The report should also identify the correction, the evidence that it worked and the treatment of affected results. This enquiry complements a batch HPLC/MS review; it focuses on whether the measurement sequence can support the specific low-level result.
Questions about peptide LC-MS carryover
Does a peak in a blank prove that the supplier material is contaminated?
No. Investigate the blank’s preparation history, the preceding injection and other possible system sources before assigning the signal to a supplier lot.
Is 0.06% carryover always acceptable?
No. The denominator and intended measurement matter. A small fraction of a high sample can be substantial relative to a low-level calibrator or impurity-reporting threshold.
Does the M10 20% limit apply to every peptide purity test?
No. M10 provides bioanalytical guidance within its scope. A raw-material assay or purity method needs its own justified acceptance criteria.
Can stronger needle wash solve every carryover problem?
No. The source can involve the column, preparation materials or hardware, and wash compatibility matters. Confirm the cause and evaluate the correction under the relevant failed conditions.